RhumbLine Advisers
SABS icon

RhumbLine Advisers’s SAB Biotherapeutics SABS Stock Holding History

RhumbLine Advisers’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$176K Buy
+45,164
New +$168K ﹤0.01% 3335

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RhumbLine Advisers's SABS Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 45,164 shares worth $176K. The stake represents ﹤0.01% of the portfolio and ranks #3335 among its holdings.

87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • RhumbLine Advisers held 45,164 shares of SAB Biotherapeutics worth $176K as of Q2 2026.
  • SAB Biotherapeutics was a new RhumbLine Advisers position in Q2 2026.
  • SAB Biotherapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3335 holding.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.